Pro 2013-021 (Jianfeng Group Corporate Bond Listing Announcement)-6
Release time:
2020-08-05
第九节 发行人近三年是否存在违法违规情况的说明
截至本上市公告书公告之日，发行人最近三年不存重大违法违规行为。
第十节 募集资金的运用
经公司第八届董事会第八次会议审议通过，并经2013年第一次临时股东大会审议通过：本次发行公司债券的募集资金拟用于偿还部分公司债务，补充公司流动资金，优化公司债务结构，改善公司资金状况。提请公司股东大会授权董事会根据公司财务状况等实际情况决定募集资金用于偿还公司债务和补充流动资金的金额、比例。
本期债券募集资金扣除发行费用后，用于偿还公司短期融资券，并拟用剩余资金补充营运资金。
第十一节 其他重要事项
本次债券发行后至本上市公告书公告之日，公司运转正常，未发生可能对本次债券的按期足额还本付息产生重大影响的重要事项。
第十二节 有关当事人
（一）发行人
名 称： 浙江尖峰集团股份有限公司
法定代表人： 蒋晓萌
住 所： 浙江省金华市婺江东路88号
电 话： 0579-82320582、82303537
传 真： 0579-82320582
联 系 人： 朱坚卫、付志坚
（二）保荐人（主承销商）/上市推荐人
名 称： 浙商证券股份有限公司
法定代表人： 吴承根
住 所： 杭州市杭大路1号
电 话： 0571-87902082、87903124
传 真： 0571-87902749
项目主办人： 华佳、周亮
项目组人员： 马岩笑、文旋、蒋盈
（三）分销商
名 称： 中信建投证券股份有限公司
法定代表人： 王常青
住 所： 北京市朝阳区安立路66号4号楼
电 话： 010-85130466
传 真： 010-85130542
联 系 人： 张慎祥、郭严、崔璐迪
（四）律师事务所
名 称： 浙江一剑律师事务所
法定代表人： 陈雄武
住 所： 浙江省金华市李渔路1018号环球商务大厦A座二楼
联 系 人： 陈雄武、左文辉
邮 编： 321017
电 话： 0579-82056936
传 真： 0579-82057299
（五）会计师事务所
名 称： 天健会计师事务所（特殊普通合伙）
法定代表人： 胡少先
住 所： 杭州市西溪路128号新湖商务大厦9楼
电 话： 0571-88216761、0571-88216764
传 真： 0571-88216870
经办会计师： 钟建国、毛晓东
（六）担保人
名 称： 天津天士力集团有限公司
法定代表人： 闫希军
住 所： 天津北辰科技园区
联 系 人： 王永胜
邮 编： 300410
电 话： 022-26736723
传 真： 022-26736720
（七）资信评级机构
名 称： 联合信用评级有限公司
法定代表人： 吴金善
住 所： 天津市南开水上公园北道38号爱俪园公寓508
电 话： 022-58356912
传 真： 022-58356989
评级人员： 刘洪涛、罗昌明
（八）本期债券受托管理人
名 称： 浙商证券股份有限公司
法定代表人： 吴承根
住 所： 杭州市杭大路1号
电 话： 0571-87902082、87903124
传 真： 0571-87902749
联 系 人： 华佳、马岩笑
（九）申请上市的证券交易所
名 称： 上海证券交易所
法定代表人： 黄红元
住 所： 上海市浦东南路528号上海证券大厦
电 话： 021-68808888
传 真： 021-68804868
（十）公司债券登记机构
名 称： 中国证券登记结算有限责任公司上海分公司
总 经 理： 高斌
住 所： 上海市浦东新区陆家嘴东路166号中国保险大厦36楼
电 话： 021-38874800
传 真： 021-58754185
第十三节 备查文件
除本上市公告书披露的资料外，备查文件如下：
一、浙江尖峰集团股份有限公司公开发行公司债券（第一期）募集说明书及其摘要；
二、中国证监会核准本次发行的文件；
三、债券受托管理协议；
四、债券持有人会议规则；
五、其他有关上市申请文件。
投资者可至发行人或保荐人（主承销商）处查阅本上市公告书全文及上述备查文件。
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page